AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in phosphatidylethanolamine (PE)
Number of subjects: 241
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation at 30th week of gestation
Number of subjects: 241
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation at delivery
Number of subjects: 241
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in cord lipids
Number of subjects: 241
Study 21141000 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 182
Study 21141000 — intervention group
Group type: COMPARATOR
Intervention: Small Incision Cataract Surgery (SICS)
Number of subjects: 182
Study 21141000 — intervention group
Group type: COMPARATOR
Intervention: SICS
Number of subjects: 182
Study 16473752 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 2 weeks)
Number of subjects: 6
Study 12738015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 20%
Number of subjects: 30
Study 12738015 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 7.5%
Number of subjects: 30
Study 12738015 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 30
Study 10695943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral fluoride releasing device (IFRD) consisting of sodium fluoride encased in an acrylic polymer, releasing fluoride at approximately 0.04 mg/day
Number of subjects: 49
Study 10695943 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 49
Study 9085402 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4, 8, 16 mg)
Number of subjects: 8
Study 9085402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (9 and 18 mg)
Number of subjects: 8
Study 9085402 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 9085402 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance buprenorphine plus challenge buprenorphine
Number of subjects: 8
Study 8335191 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight) combined with prednisolone (60 mg daily tapering to 10 mg)
Number of subjects: 42
Study 8335191 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (60 mg daily tapering to 10 mg) monotherapy
Number of subjects: 42
Study 8335191 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight) combined with prednisolone
Number of subjects: 42
Study 8335191 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone monotherapy
Number of subjects: 42
Study 2883488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 188
Study 2883488 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (300 mg base weekly)
Number of subjects: 188
Study 2883488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 188
Study 29215954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (intraperitoneal group)
Number of subjects: 244
Study 29215954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (intraincisional group)
Number of subjects: 244
Study 29215954 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 244
Study 27608926 — intervention group
Group type: EXPERIMENTAL
Intervention: THPP+ intervention (bimonthly group‐based sessions for 36 months)
Number of subjects: 560
Study 27608926 — intervention group
Group type: COMPARATOR
Intervention: Control group (perinatally nondepressed women)
Number of subjects: 560
Study 24525661 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (4 to 8 mg twice daily)
Number of subjects: 215
Study 24525661 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (12 to 16 mg twice daily)
Number of subjects: 215
Study 24525661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 23212499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically integrated e-learning EBM course
Number of subjects: 204
Study 23212499 — intervention group
Group type: COMPARATOR
Intervention: Self-directed EBM course
Number of subjects: 204
Study 20162706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine (2000 mg/50 mL) twice weekly for 6 weeks, then weekly for 3 weeks at 3, 6, and 12 months
Number of subjects: 80
Study 20162706 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6-week induction course and weekly for 3 weeks at 3, 6, and 12 months
Number of subjects: 80
Study 20162706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 80
Study 20162706 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 80
Study 18417130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound
Number of subjects: 0
Study 18417130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 15917336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg daily
Number of subjects: 61
Study 15917336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTF)
Number of subjects: 61
Study 14699228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine omitted on the night before surgery (Group 1)
Number of subjects: 14
Study 14699228 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine continued with morning dose on the day of surgery (Group 2)
Number of subjects: 14
Study 10805066 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel 800 mg loading dose followed by 100-, 200-, or 400-mg maintenance doses every 12 hours for five doses
Number of subjects: 0
Study 8857482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 36
Study 8857482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7963447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg/day
Number of subjects: 3396
Study 7963447 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin 75-150 mg/day
Number of subjects: 3396
Study 7963447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3396
Study 7963447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 3396
Study 3308579 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffy coat transfusions (approximately 0.6 X 10(9) T-lymphocytes) weekly for 5 weeks
Number of subjects: 22
Study 3308579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no buffy coat transfusions)
Number of subjects: 22
Study 29417834 — intervention group
Group type: EXPERIMENTAL
Intervention: teen Mental Health First Aid (tMHFA)
Number of subjects: 1942
Study 29417834 — intervention group
Group type: COMPARATOR
Intervention: Physical First Aid (PFA)
Number of subjects: 1942
Study 27327608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training towards affective pain words (S+A+)
Number of subjects: 106
Study 27327608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training towards sensory pain words (S+A-)
Number of subjects: 106
Study 27327608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training away from affective pain words (S-A+)
Number of subjects: 106
Study 27327608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training away from sensory pain words (S-A-)
Number of subjects: 106
Study 27327608 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study 24763133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 750 mg
Number of subjects: 127
Study 24763133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 23865726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol (flutiform) 250/10 µg b.i.d.
Number of subjects: 0
Study 23865726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol (flutiform)
Number of subjects: 0
Study 23865726 — intervention group
Group type: COMPARATOR
Intervention: SKP FP
Number of subjects: 0
Study 23865726 — intervention group
Group type: COMPARATOR
Intervention: GSK FP
Number of subjects: 0
Study 22352202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) therapy added to NIAAA protocol for 2004
Number of subjects: 240
Study 22352202 — intervention group
Group type: COMPARATOR
Intervention: NIAAA protocol for 2004 (Control group)
Number of subjects: 240
Study 19043252 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 0
Study 19043252 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB; amlodipine or nifedipine)
Number of subjects: 0
Study 17190587 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 1719
Study 17190587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-laparotomy cholecystectomy
Number of subjects: 1719
Study 17190587 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 1719
Study 17190587 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised patients
Number of subjects: 1719
Study 17190587 — intervention group
Group type: COMPARATOR
Intervention: Trial patients
Number of subjects: 1719
Study 12747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Number of subjects: 40
Study 12747340 — intervention group
Group type: COMPARATOR
Intervention: High flow anesthesia
Number of subjects: 40
Study 10959505 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional overnight co-incubation of sperm and oocytes
Number of subjects: 0
Study 10959505 — intervention group
Group type: COMPARATOR
Intervention: Short (2-h) co-incubation of sperm and oocytes
Number of subjects: 0
Study 8580386 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 levels
Number of subjects: 13
Study 8580386 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 13
Study 8580386 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastase-alpha 1-AT levels
Number of subjects: 13
Study 8580386 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 and IL-6 interrelation
Number of subjects: 13
Study 8580386 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 and elastase complexes
Number of subjects: 13
Study 2550642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 304
Study 2550642 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg once daily
Number of subjects: 304
Study 2550642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily with hydrochlorothiazide 25 mg
Number of subjects: 304
Study 2550642 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg once daily with hydrochlorothiazide 25 mg
Number of subjects: 304
Study 363215 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 126
Study 363215 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 126
Study 363215 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV) and Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 126
Study 31082267 — intervention group
Group type: EXPERIMENTAL
Intervention: Information film + written information booklet
Number of subjects: 229
Study 28785746 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishment (A: n = 21)
Number of subjects: 23
Study 28785746 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement (B: n = 21)
Number of subjects: 23
Study 28785746 — intervention group
Group type: COMPARATOR
Intervention: Untreated (C: n = 21)
Number of subjects: 23
Study 26181802 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing a videogame with a sexualized female character for 15 minutes
Number of subjects: 57
Study 26181802 — intervention group
Group type: COMPARATOR
Intervention: Control condition (playing a videogame with a nonsexualized female character)
Number of subjects: 57
Study 23123272 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 10
Study 21964278 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based classification methods
Number of subjects: 115
Study 18624823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 241
Study 18624823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 241
Study 16672214 — intervention group
Group type: EXPERIMENTAL
Intervention: Coleus amboinicus Lour (CA) supplementation
Number of subjects: 0
Study 16672214 — intervention group
Group type: COMPARATOR
Intervention: Molocco+B12 tablets
Number of subjects: 0
Study 16672214 — intervention group
Group type: COMPARATOR
Intervention: Fenugreek seeds
Number of subjects: 0
Study 15610110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg (with option to titrate to 5, 10, or 20 mg)
Number of subjects: 463
Study 15610110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 463
Study 15610110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 11377409 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (started at 25 mg/day, titrated up to 250 mg/day)
Number of subjects: 83
Study 11377409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11377409 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 83
Study 8113283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with radiographic signs of prosthetic loosening
Number of subjects: 49
Study 8113283 — intervention group
Group type: COMPARATOR
Intervention: Patients without radiographic signs of prosthetic loosening
Number of subjects: 49
Study 3336109 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver oxide coating of the indwelling urethral catheter and catheter adapter, and instillation of trichloroisocyanuric acid into the urinary drainage bag
Number of subjects: 74
Study 3336109 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard catheter care)
Number of subjects: 74
Study 3336109 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroisocyanuric acid
Number of subjects: 74
Study 3336109 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial agents
Number of subjects: 74
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HBV/HCV co-infection
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HBV co-infection
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple infection
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV infection rate
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV co-infection
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection rates among widowed patients
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk behavior
Number of subjects: 311
Study 31880494 — intervention group
Group type: EXPERIMENTAL
Intervention: Other risk factors
Number of subjects: 311
Study 30406565 — intervention group
Group type: COMPARATOR
Intervention: Anti-citrullinated α-enolase peptide 1 antibodies (a-CEP-1)
Number of subjects: 74
Study 30406565 — intervention group
Group type: COMPARATOR
Intervention: Anti-mutated citrullinated vimentin antibodies (a-Sa)
Number of subjects: 74
Study 30406565 — intervention group
Group type: COMPARATOR
Intervention: Anti-caramylated protein antibodies (a-CarP)
Number of subjects: 74
Study 30406565 — intervention group
Group type: COMPARATOR
Intervention: Anti-hnRNP/RA33 antibodies (a-hnRNP/RA33)
Number of subjects: 74
Study 30406565 — intervention group
Group type: COMPARATOR
Intervention: Anti-filaggrin antibodies (AFAs)
Number of subjects: 74
Study 28950361 — intervention group
Group type: EXPERIMENTAL
Intervention: GAVS II risk model applied to the validation group
Number of subjects: 18054
Study 26632177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Rice Bran Supercritical CO2 Extract (RB-SCE) applied dermally (8 mL/d) for 16 weeks
Number of subjects: 50
Study 26632177 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied dermally for 16 weeks
Number of subjects: 50
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 8 mg BID
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 12 mg BID
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg QD
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg BID
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 375 mg BID
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone with metabolic inhibitors (paroxetine and ketoconazole)
Number of subjects: 188
Study 23277250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 188
Study 21199881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine
Number of subjects: 1030
Study 21199881 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical malaria during pregnancy
Number of subjects: 1030
Study 21199881 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute placental infection
Number of subjects: 1030
Study 18164818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5mg BID
Number of subjects: 522
Study 18164818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 1mg QD
Number of subjects: 522
Study 18164818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 1mg BID
Number of subjects: 522
Study 18164818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522
Study 16437269 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair (OR) under local anesthesia
Number of subjects: 61
Study 16437269 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic repair (LR) under general anesthesia
Number of subjects: 61
Study 14609923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419
Study 14609923 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 419
Study 10934078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin monotherapy with reevaluation at 3 days
Number of subjects: 81
Study 10934078 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (choice and duration of antibiotics at the discretion of physicians)
Number of subjects: 81
Study 10934078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin monotherapy
Number of subjects: 81
Study 10934078 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 81
Study 8681595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.5 mg/kg/hr iv) for 5 days in trauma patients (n = 15)
Number of subjects: 60
Study 8681595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.5 mg/kg/hr iv) for 5 days in sepsis patients (n = 15)
Number of subjects: 60
Study 8681595 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo in trauma patients (n = 15)
Number of subjects: 60
Study 8681595 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo in sepsis patients (n = 15)
Number of subjects: 60
Study 1558329 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG modified grass pollen mix allergen preparation (mPEG‐gm)
Number of subjects: 30
Study 1558329 — intervention group
Group type: COMPARATOR
Intervention: Partly purified grass pollen mix allergen preparation (gm)
Number of subjects: 30
Study 1558329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments at high dose levels (120,000 BU)
Number of subjects: 30
Study 6395323 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (Cyklocapron, 4.5 g per day for 6 weeks)
Number of subjects: 45
Study 31433269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3000 mg/day, 1053 mg omega-3 fatty acids) plus wheat germ oil (300 mg/day, 0.765 mg vitamin E)
Number of subjects: 46
Study 31433269 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 46
Study 31074700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (5-7 days/week, energy expenditure 2,100-4,200 kcal/week for men and 1,600 kcal/week for women)
Number of subjects: 124
Study 30672216 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-promotion needling method (acupuncture with filiform needle, warm promotion with fire needle, and bleeding technique with three-edged needle)
Number of subjects: 70
Study 30672216 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (1mg orally before sleep, once every 2 days for 4 weeks)
Number of subjects: 70
Study 28065228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu Aura-i
Number of subjects: 120
Study 28065228 — intervention group
Group type: COMPARATOR
Intervention: Air-Q
Number of subjects: 120
Study 24615079 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 24615079 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 20978932 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 360
Study 20027432 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary system
Number of subjects: 20
Study 20027432 — intervention group
Group type: COMPARATOR
Intervention: Nitiflex files
Number of subjects: 20
Study 16697316 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 16697316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 14759439 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump (CABG)
Number of subjects: 160
Study 14759439 — intervention group
Group type: COMPARATOR
Intervention: Off-pump (OPCAB)
Number of subjects: 160